vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.
SMITH & WESSON BRANDS, INC. is the larger business by last-quarter revenue ($124.7M vs $83.5M, roughly 1.5× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs 1.5%, a 5.3% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -3.9%). SMITH & WESSON BRANDS, INC. produced more free cash flow last quarter ($16.3M vs $6.5M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
BLLN vs SWBI — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $124.7M |
| Net Profit | $5.7M | $1.9M |
| Gross Margin | 69.9% | 24.3% |
| Operating Margin | 11.5% | 3.3% |
| Net Margin | 6.8% | 1.5% |
| Revenue YoY | 117.4% | -3.9% |
| Net Profit YoY | 138.3% | -53.6% |
| EPS (diluted) | $0.10 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $124.7M | ||
| Q3 25 | $83.5M | $85.1M | ||
| Q2 25 | — | $140.8M | ||
| Q1 25 | — | $115.9M | ||
| Q4 24 | — | $129.7M | ||
| Q3 24 | $38.4M | $88.3M | ||
| Q2 24 | — | $159.1M | ||
| Q1 24 | — | $137.5M |
| Q4 25 | — | $1.9M | ||
| Q3 25 | $5.7M | $-3.4M | ||
| Q2 25 | — | $8.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $-14.9M | $-1.9M | ||
| Q2 24 | — | $27.9M | ||
| Q1 24 | — | $7.9M |
| Q4 25 | — | 24.3% | ||
| Q3 25 | 69.9% | 25.9% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | — | 24.1% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | 52.6% | 27.4% | ||
| Q2 24 | — | 35.5% | ||
| Q1 24 | — | 28.7% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | 11.5% | -3.5% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | -32.9% | -1.7% | ||
| Q2 24 | — | 17.4% | ||
| Q1 24 | — | 8.2% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | 6.8% | -4.0% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | -38.8% | -2.1% | ||
| Q2 24 | — | 17.5% | ||
| Q1 24 | — | 5.7% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | $0.10 | $-0.08 | ||
| Q2 25 | — | $0.19 | ||
| Q1 25 | — | $0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | $-1.47 | $-0.04 | ||
| Q2 24 | — | $0.60 | ||
| Q1 24 | — | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $22.4M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $363.2M |
| Total Assets | $327.5M | $548.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $22.4M | ||
| Q3 25 | $195.2M | $18.0M | ||
| Q2 25 | — | $25.2M | ||
| Q1 25 | — | $26.7M | ||
| Q4 24 | — | $39.1M | ||
| Q3 24 | — | $35.5M | ||
| Q2 24 | — | $60.8M | ||
| Q1 24 | — | $47.4M |
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $363.2M | ||
| Q3 25 | $-239.5M | $364.4M | ||
| Q2 25 | — | $372.5M | ||
| Q1 25 | — | $366.9M | ||
| Q4 24 | — | $371.5M | ||
| Q3 24 | $-242.9M | $380.0M | ||
| Q2 24 | — | $399.9M | ||
| Q1 24 | — | $376.4M |
| Q4 25 | — | $548.6M | ||
| Q3 25 | $327.5M | $554.6M | ||
| Q2 25 | — | $559.6M | ||
| Q1 25 | — | $578.9M | ||
| Q4 24 | — | $587.4M | ||
| Q3 24 | — | $571.3M | ||
| Q2 24 | — | $577.4M | ||
| Q1 24 | — | $570.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $27.3M |
| Free Cash FlowOCF − Capex | $6.5M | $16.3M |
| FCF MarginFCF / Revenue | 7.7% | 13.1% |
| Capex IntensityCapex / Revenue | 8.8% | 8.8% |
| Cash ConversionOCF / Net Profit | 2.42× | 14.22× |
| TTM Free Cash FlowTrailing 4 quarters | — | $21.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.3M | ||
| Q3 25 | $13.8M | $-8.1M | ||
| Q2 25 | — | $40.8M | ||
| Q1 25 | — | $-9.8M | ||
| Q4 24 | — | $-7.4M | ||
| Q3 24 | — | $-30.8M | ||
| Q2 24 | — | $43.7M | ||
| Q1 24 | — | $25.2M |
| Q4 25 | — | $16.3M | ||
| Q3 25 | $6.5M | $-12.4M | ||
| Q2 25 | — | $33.5M | ||
| Q1 25 | — | $-16.1M | ||
| Q4 24 | — | $-10.7M | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $38.2M | ||
| Q1 24 | — | $7.0M |
| Q4 25 | — | 13.1% | ||
| Q3 25 | 7.7% | -14.6% | ||
| Q2 25 | — | 23.8% | ||
| Q1 25 | — | -13.9% | ||
| Q4 24 | — | -8.3% | ||
| Q3 24 | — | -40.2% | ||
| Q2 24 | — | 24.0% | ||
| Q1 24 | — | 5.1% |
| Q4 25 | — | 8.8% | ||
| Q3 25 | 8.8% | 5.0% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.3% | ||
| Q2 24 | — | 3.5% | ||
| Q1 24 | — | 13.2% |
| Q4 25 | — | 14.22× | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | 4.73× | ||
| Q1 25 | — | -4.68× | ||
| Q4 24 | — | -1.63× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | — | 3.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
SWBI
Segment breakdown not available.
